A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus
Objective To assess the real-world efficacy and safety of the first sodium-glucose cotransporter-2 inhibitor, canagliflozin, in the treatment of patients with type 2 diabetes mellitus (T2DM). Methods This observational study assessed the efficacy and tolerability of canagliflozin in T2DM patients. P...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2014-01-01
|
| Series: | Clinical Medicine Insights: Endocrinology and Diabetes |
| Online Access: | https://doi.org/10.4137/CMED.S18182 |
| _version_ | 1818807549906911232 |
|---|---|
| author | AnneMarie Nardolillo Michael P. Kane Robert S. Busch Jay Watsky Robert A. Hamilton |
| author_facet | AnneMarie Nardolillo Michael P. Kane Robert S. Busch Jay Watsky Robert A. Hamilton |
| author_sort | AnneMarie Nardolillo |
| collection | DOAJ |
| description | Objective To assess the real-world efficacy and safety of the first sodium-glucose cotransporter-2 inhibitor, canagliflozin, in the treatment of patients with type 2 diabetes mellitus (T2DM). Methods This observational study assessed the efficacy and tolerability of canagliflozin in T2DM patients. Primary study outcomes were changes in HbAlC and weight, and percentage of patients reporting adverse effects of therapy. Results The study criteria were met by 111 patient records. Baseline patient characteristics were: average age, 59 ± 9 years; mean duration of T2DM, 11.9 ± 7.3 years; 57.6% of patients were male; 92.8% were Caucasian; baseline BMI, 38.9 ± 11 kg/m 2 ; and mean baseline HbAlC, 7.53 (58.8 mmol/mol) ± 1.08%. HbAlC and weight were significantly reduced by 0.37% and 4.4 kg, respectively. Adverse effects were reported by 21 patients, and 17 (15.3%) discontinued canagliflozin because of adverse reactions. Conclusion Canagliflozin was generally well tolerated and significantly reduced HbAlC levels and body weight in patients with T2DM when added to a regimen of other anti-hyperglycemic agents. |
| first_indexed | 2024-12-18T19:27:26Z |
| format | Article |
| id | doaj.art-e3dedcf23ea0427eb8887ad9d04e3c09 |
| institution | Directory Open Access Journal |
| issn | 1179-5514 |
| language | English |
| last_indexed | 2024-12-18T19:27:26Z |
| publishDate | 2014-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Endocrinology and Diabetes |
| spelling | doaj.art-e3dedcf23ea0427eb8887ad9d04e3c092022-12-21T20:55:50ZengSAGE PublishingClinical Medicine Insights: Endocrinology and Diabetes1179-55142014-01-01710.4137/CMED.S18182A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes MellitusAnneMarie Nardolillo0Michael P. Kane1Robert S. Busch2Jay Watsky3Robert A. Hamilton4Albany College of Pharmacy and Health Sciences, Albany, NY.Albany College of Pharmacy and Health Sciences, Albany, NY.The Endocrine Group, LLP, Albany, NY.The Endocrine Group, LLP, Albany, NY.Albany College of Pharmacy and Health Sciences-Vermont Campus, Colchester, VT.Objective To assess the real-world efficacy and safety of the first sodium-glucose cotransporter-2 inhibitor, canagliflozin, in the treatment of patients with type 2 diabetes mellitus (T2DM). Methods This observational study assessed the efficacy and tolerability of canagliflozin in T2DM patients. Primary study outcomes were changes in HbAlC and weight, and percentage of patients reporting adverse effects of therapy. Results The study criteria were met by 111 patient records. Baseline patient characteristics were: average age, 59 ± 9 years; mean duration of T2DM, 11.9 ± 7.3 years; 57.6% of patients were male; 92.8% were Caucasian; baseline BMI, 38.9 ± 11 kg/m 2 ; and mean baseline HbAlC, 7.53 (58.8 mmol/mol) ± 1.08%. HbAlC and weight were significantly reduced by 0.37% and 4.4 kg, respectively. Adverse effects were reported by 21 patients, and 17 (15.3%) discontinued canagliflozin because of adverse reactions. Conclusion Canagliflozin was generally well tolerated and significantly reduced HbAlC levels and body weight in patients with T2DM when added to a regimen of other anti-hyperglycemic agents.https://doi.org/10.4137/CMED.S18182 |
| spellingShingle | AnneMarie Nardolillo Michael P. Kane Robert S. Busch Jay Watsky Robert A. Hamilton A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus Clinical Medicine Insights: Endocrinology and Diabetes |
| title | A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus |
| title_full | A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus |
| title_fullStr | A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus |
| title_full_unstemmed | A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus |
| title_short | A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus |
| title_sort | clinical perspective of canagliflozin in the management of type 2 diabetes mellitus |
| url | https://doi.org/10.4137/CMED.S18182 |
| work_keys_str_mv | AT annemarienardolillo aclinicalperspectiveofcanagliflozininthemanagementoftype2diabetesmellitus AT michaelpkane aclinicalperspectiveofcanagliflozininthemanagementoftype2diabetesmellitus AT robertsbusch aclinicalperspectiveofcanagliflozininthemanagementoftype2diabetesmellitus AT jaywatsky aclinicalperspectiveofcanagliflozininthemanagementoftype2diabetesmellitus AT robertahamilton aclinicalperspectiveofcanagliflozininthemanagementoftype2diabetesmellitus AT annemarienardolillo clinicalperspectiveofcanagliflozininthemanagementoftype2diabetesmellitus AT michaelpkane clinicalperspectiveofcanagliflozininthemanagementoftype2diabetesmellitus AT robertsbusch clinicalperspectiveofcanagliflozininthemanagementoftype2diabetesmellitus AT jaywatsky clinicalperspectiveofcanagliflozininthemanagementoftype2diabetesmellitus AT robertahamilton clinicalperspectiveofcanagliflozininthemanagementoftype2diabetesmellitus |